Iterum Therapeutics Receives Approval to Transfer to Nasdaq Capital Market
21 déc. 2020 17h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 21, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Filing of US Patent Application Based on Favorable Written Opinion of the International Search Authority
07 déc. 2020 08h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Submits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
30 nov. 2020 09h15 HE
|
Iterum Therapeutics plc
--First Oral Penem in the U.S. and First New Oral Treatment for uUTIs in Over 20 Years, if approved-- --Potential Approval Q3 2021 with Priority Review-- DUBLIN, Ireland and CHICAGO, Nov. 30,...
Iterum Therapeutics Reports Third Quarter 2020 Financial Results
16 nov. 2020 06h45 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
Iterum Therapeutics Announces Pricing of $17.5 Million Upsized Public Offering
23 oct. 2020 00h02 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 23, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV...
UPDATE -- Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
19 oct. 2020 19h10 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics to Present Data from Phase 3 Trials in Uncomplicated and Complicated Urinary Tract Infections at IDWeek 2020
19 oct. 2020 18h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Positive Pre-NDA Meeting with FDA for Sulopenem for Treatment of Uncomplicated Urinary Tract Infections
30 sept. 2020 07h00 HE
|
Iterum Therapeutics plc
--Preparing to Submit NDA in Q4-- DUBLIN, Ireland and CHICAGO, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company...
Iterum Therapeutics to Present at the 22nd Annual H.C. Wainwright Global Investment Conference
08 sept. 2020 16h30 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...
Iterum Therapeutics Announces Revised Results of Rights Offering
02 sept. 2020 07h00 HE
|
Iterum Therapeutics plc
DUBLIN, Ireland and CHICAGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation...